Blue Trust Inc’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-1,125
Closed -$18.5K – 2532
2024
Q4
$18.5K Sell
1,125
-2,193
-66% -$34.1K ﹤0.01% 1619
2024
Q3
$46K Buy
3,318
+987
+42% +$15.4K ﹤0.01% 1604
2024
Q2
$36.6K Buy
2,331
+1,206
+107% +$17.1K ﹤0.01% 1393
2024
Q1
$17.7K Sell
1,125
-519
-32% -$8.01K ﹤0.01% 1273
2023
Q4
$21K Sell
1,644
-606
-27% -$9.92K ﹤0.01% 1266
2023
Q3
$36K Hold
2,250
– – ﹤0.01% 968
2023
Q2
$39K Sell
2,250
-70
-3% -$1.15K ﹤0.01% 786
2023
Q1
$21K Buy
2,320
+17
+0.7% +$242 ﹤0.01% 1346
2022
Q4
$20K Hold
2,303
– – ﹤0.01% 1300
2022
Q3
$19K Sell
2,303
-3
-0.1% -$30 ﹤0.01% 1117
2022
Q2
$28K Buy
+2,306
New +$22K ﹤0.01% 853

Other funds holding NEO

Blue Trust Inc's NEO Position: Q1 2025 in Review

Blue Trust Inc sold out of NeoGenomics (NEO) in Q1 2025, closing a stake of 1,125 shares — an estimated $18.5K sold.

Blue Trust Inc first reported a position in NEO in Q2 2022 and held it in 11 quarters. The position peaked at $46K in Q3 2024. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2025.

  • Blue Trust Inc reported no remaining NeoGenomics position as of Q1 2025 after selling out during the quarter.
  • Blue Trust Inc sold 1,125 NeoGenomics shares in Q1 2025, an estimated $18.5K.
  • Blue Trust Inc first reported a position in NeoGenomics in Q2 2022 and held it in 11 quarters.
  • Blue Trust Inc's NeoGenomics position peaked at $46K in Q3 2024.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2025.

Based on Blue Trust Inc's 13F filing for Q1 2025, filed 21 Apr 2025.